{"id":"W2588395233","doi":"10.1093/annonc/mdw365.94","title":"HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Anthracycline; Internal medicine; Metastatic breast cancer; Trastuzumab emtansine; Taxane; Oncology; Clinical endpoint; Capecitabine; Vinorelbine; Breast cancer; Epirubicin; Chemotherapy; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001212464,0.001744431,0.00232441,0.0004949371,0.0003412566,0.001145135,0.0009748255,0.001443164,0.009190636],"category_scores_gemma":[0.001280638,0.0005457001,0.001570658,0.0003868319,0.00106272,0.001152791,0.0004378195,0.00305412,0.001432643],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007339529,"about_ca_system_score_gemma":0.001269535,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001007932,"about_ca_topic_score_gemma":0.002738154,"domain_scores_codex":[0.9996648,0.0001630347,0.00001577337,0.00007281077,0.00001865013,0.00006496994],"domain_scores_gemma":[0.9995229,0.0001187028,0.0000870543,0.00003353216,0.0000176307,0.0002201576],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9677864,0.01050834,0.0005765893,0.0004468305,0.0006272044,0.00003883571,0.00005212099,0.0005182598,0.003245619,0.000235707,0.001330723,0.01463343],"study_design_scores_gemma":[0.9487022,0.04888257,0.0009252621,0.000018884,0.000212188,0.00002223004,0.00001797074,0.0002386336,0.0002226909,0.000121395,0.0006255584,0.00001043755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826788,0.003646343,0.000732845,0.001383225,0.0009647298,0.003865564,0.001953326,0.0002680491,0.004507203],"genre_scores_gemma":[0.9727716,0.003107798,0.002688366,0.002314613,0.0008596856,0.005553931,0.00307637,0.0000555379,0.009572198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009190636,"threshold_uncertainty_score":0.0307458,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0772610085246743,"score_gpt":0.4431137932374388,"score_spread":0.3658527847127645,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}